[1]李玮,谭建.肿瘤基因治疗相关的特异性启动子研究新进展[J].国际放射医学核医学杂志,2014,38(3):185-189.[doi:10.3760/cma.j.issn.1673-4114.2014.03.011]
 Li Wei,Tan Jian.The new progress of the specific promoter for cancer gene therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):185-189.[doi:10.3760/cma.j.issn.1673-4114.2014.03.011]
点击复制

肿瘤基因治疗相关的特异性启动子研究新进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第3期
页码:
185-189
栏目:
出版日期:
2014-05-25

文章信息/Info

Title:
The new progress of the specific promoter for cancer gene therapy
作者:
李玮 谭建
300052 天津, 天津医科大学总医院核医学科
Author(s):
Li Wei Tan Jian
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
启动区(遗传学)基因疗法靶向疗法
Keywords:
Promoter regions(Genetics)Gene therapyTargeted therapy
DOI:
10.3760/cma.j.issn.1673-4114.2014.03.011
摘要:
肿瘤基因治疗是一种在基因水平上治疗肿瘤的方法,是现有治疗肿瘤的先进方法之一。但是,肿瘤基因治疗技术还存在很多未解决的问题,例如目的基因表达的靶向性问题等。现有研究证实,使用特异性启动子可以提高肿瘤基因治疗的靶向性。启动子是指能启动mRNA转录的一段特异性DNA序列,特异性启动子是指仅在特定组织或肿瘤中才会被激活的启动子。该文将就肿瘤基因治疗相关的特异性启动子的近期研究,按启动子的作用类型进行综述。
Abstract:
Cancer gene therapy is a way to treat cancer at the gene level which is one of the effec-tive methods for cancer therapy.But,there are still some outstanding problems,for example,the targeting of gene expression.Recent researches confirm that the specific promoter can improve the targeting in gene therapy.The promoter is a region of DNA which can initiates transcription of a particular gene.The specif-ic promoter only can be activated in certain tissue or tumor.Based on the recent studies in this field,this article will introduce types and functions of specific promoters,which has been investigated in cancer gene therapy.

参考文献/References:

[1] Lu Y,Zhang Y,Chang G,et al.Compar ison of prostate-specific promoters and the use of psp-driven virotherapy for prostate cancer[J/OL].Biomed Res Int,2013,2013:624632[2013-12-01].http://www.ncbi.nlm.nih.gov/pubmed/23484134.
[2] Baiz D,Hassan S,Choi YA,et al.Combination of the PI3k inhibitor zstk474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer[J].Neoplasia,2013,15(10):1172-1183.
[3] Claessens F,Rushmere NK,Davies P,et al.Sequence-specific binding of androgen-receptor complexes to prostatic binding protein genes[J].Mol Cell Endocrinol,1990,74(3):203-212.
[4] Kesmodel S,Prabakaran I,Canter R,et al.Virus-mediated oncoly-sis of thyroid cancer by a replication-selective adenovirus driven by a thyroglobulin promoter-enhancer region[J].J Clin Endocrinol Metab,2005,90(6):3440-3448.
[5] Spitzweg C,Baker CH,Bergert ER,et al.Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression[J].Hum Gene Ther,2007,18(10):916-924.
[6] Chen EQ,Song XQ,Wang YL,et al.Construction of a highly-ac-tive,liver-specific transcriptional regulatory element through com-bination of the albumin promoter and alpha-fetoprotein enhancer[J].Plasmid,2010,65(2):125-131.
[7] Horst M,Brouwer E,Verwijnen S,et al.Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective on-colytic adenovirus[J].J Gene Med,2007,9(12):1071-1079.
[8] Li W,Tan J,Wang P,et al.The glial fibrillary acidic protein pro-moter directs sodium/iodide symporter gene expression for radioio-dine therapy of malignant glioma[J].Oncol Lett,2013,5(2):669-674.
[9] Tanaka M,Inase N,Miyake S,et al.Neuron specific enolase pro-moter for suicide gene therapy in small cell lung carcinoma[J].An-ticancer Res,2001,21(1A):291-294.
[10] Jin C,Yu D,?an?er M,et al.Tat-PTD-modified oncolytic aden-ovirus driven by the SCG3 promoter and ASH1 enhancer for neu-roblastoma therapy[J].Hum Gene Ther.2013,24(8):766-775.
[11] Peng YF,Shi YH,Ding ZB,et al.a-Fetoprotein promoter-driven Cre/Loxp-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy[J/OL].PLoS One,2013,8(2):e53072.http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053072
[12] Zhou X,Xie G,Wang S,et al.Potent and specific antitumor effect for colorectal cancer by CEAand Rbdouble regulated oncolytic adenovirus harboring ST13 gene[J/OL].PLoS One,2012,7(10):e47566.http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0047566.
[13] Qiu Y,Peng GL,Liu QC,et al.Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes,thymidine kinase and cytosine deaminase (pCEA-TK/CD)[J].Can-cer Lett,2012,316(1):31-38.
[14] Guo X,Evans TR,Somanath S,et al.In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluo-rouracil prodrug gene therapy in colon cancer cell lines[J].Br J Cancer,2007,97(6):745-754.
[15] Yi T,Papadopoulos E,Hagner PR,et al.Hypoxia-inducible factor-1a (HIF-1a) promotes cap-dependent translation of selective mR-NAs through up-regulating initiation factor eIFf4E1 in breast can-cer cells under hypoxia conditions[J].J Biol Chem,2013,288(26):18732-18742.
[16] Doloff JC,Jounaidi Y,Waxman DJ.Dual E1A oncolytic aden-ovirus:targeting tumor heterogeneity with two independent can-cer-specific promoter elements,DF3/MUC1 and hTERT[J].Cancer Gene Ther,2011,18(3):153-166.
[17] Trujillo MA,Oneal MJ,Davydova J,et al.Construction of an MUC-1 promoter driven,conditionally replicating adenovirus that ex-presses the sodium iodide symporter for gene therapy of breast can-cer[J].Breast Cancer Res,2009,11(4):R53.
[18] Won YS,Lee SW.Cancer-specific induction of adenoviral E1A ex-pression by group Iintron-based trans-splicing ribozyme[J].J Mi-crobiol Biotechnol,2012,22(3):431-435.
[19] Rajecki M,Sarparanta M,Hakkarainen T,et al.SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic aden-ovirus and 131I[J/OL].PLoS One,2012,7(3):e32871.http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0032871.
[20] Li W,Tan J,Wang P,et al.Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase re-verse transcriptase promoter for targeted radioiodine therapy of ma-lignant glioma cells[J].Cancer Biother Radiopharm,2011,26(4):443-451.
[21] Chen J,Yang B,Zhang S,et al.Antitumor potential of SLPI pro-moter controlled recombinant caspase-3 expression in laryngeal carcinoma[J].Cancer Gene Ther,2012,19(5):328-335.
[22] Maemondo M,Saijo Y,Narumi K,et al.Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer[J].Cancer Res,2004,64(13):4611-4620.
[23] Barker SD,Coolidge CJ,Kanerva A,et al.The secretory leukopro-tease inhibitor (SLPI) promoter for ovarian cancer gene therapy[J].J Gene Med,2003,5(4):300-310.
[24] Niu Y,Li JS,Luo XR.Enhancement of expression of survivin pro-moter-driven CD/TK double suicide genes by the nuclear matrix at-tachment region in transgenic gastric cancer cells[J].Gene,2014,534(2):177-182.
[25] 严泽军,程跃,蒋军辉,等.Survivin启动子调控腺病毒介导富含亮氨酸重复和免疫球蛋白样结构域1基因治疗膀胱癌的实验研究[J].中华外科杂志,2012,50(8):732-736.
[26] Liu C,Sun B,An N,et al.Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallblad-der cancer[J].Mol Oncol,2011,5(6):545-554.
[27] Xiang J,Ouyang Y,Cui Y,et al.Silencing of notch3 using shRNA driven by survivin promoter inhibits growth and promotes apoptosis of human T-cell acute lymphoblastic leukemia cells[J].Clin Lym-phoma Myeloma Leuk,2012,12(1):59-65.
[28] Ma J,Li M,Mei L,et al.Double suicide genes driven by kinase do-main insert containing receptor promoter selectively kill human lung cancer cells[J].Genet Vaccines Ther,2011,9:6.
[29] Li XH,Zhou P,Wang LH,et al.The targeted gene (KDRP-CD/TK) therapy of breast cancer mediated by SonoVue and ultrasound irra-diation in vitro[J].Ultrasonics,2012,52(1):186-191.
[30] 马晓方,杜晓光,辛现良,等.肿瘤细胞恶性增殖和细胞周期调控改变的分子机制[J].现代生物医学进展,2009,9(5):950-953.
[31] Sherr CJ,McCormick F.The RB and p53 pathways in cancer[J].Cancer Cell,2002,2(2):103-112.
[32] Yan Y,Xu Y,Zhao Y,et al.Combination of E2F-1 promoter-regu-lated oncolytic adenovirus and cytokine-induced killer cells en-hances the antitumor effects in an orthotopic rectal cancer model[J].Tumour Biol,2013:35(2):1113-1122.
[33] Lin G,Lin MC,Lin S,et al.Early growth response protein-1 pro-moter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-Flurorouracil on nasopharyngeal carcinoma[J].Can-cer Biother Radiopharm,2013,27(7):434-441.
[34] Rein DT,Volkmer A,Beyer IM,et al.Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus[J].Gynecol Oncol,2011,123(1):138-146.
[35] Maeda T,O-Wang J,Matsubara H,et al.A minimum c-erbb-2 pro-moter-mediated expression of herpes simplex virus thymidine ki-nase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir[J].Cancer Gene Ther,2001,8(11):890-896.
[36] Nettelbeck DM,Jerome V,Muller R.Gene therapy:designer pro-moters for tumour targeting[J].Trends Genet,2000,16(4):174-181.
[37] Yu B,Zhang Y,Zhan Y,et al.Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects[J].Oncol Rep,2011,26(1):255-264.
[38] 李玮,谭建,王澎,等.hTERT和GFAP启动子条件限制腺病毒介导放射性碘治疗脑胶质瘤[J].中华放射医学与防护杂志,2014,34(1):1-6.

相似文献/References:

[1]王芹,王敬敏,徐畅,等.Ad-Rb94联合照射对体外人大肠癌细胞的抑瘤作用[J].国际放射医学核医学杂志,2014,38(6):351.[doi:10.3760/cma.j.issn.1673-4114.2014.06.001]
 Wang Qin,Wang Jing-min,Xu Chang,et al.The effect of Ad-Rb94 combined with radiation on inhibiting the growth of human colorectal cancer cells in vitro[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):351.[doi:10.3760/cma.j.issn.1673-4114.2014.06.001]
[2]王芹,刘晓秋,李进,等.白细胞介素21基因联合不同剂量γ射线照射对乳腺癌细胞生长的影响[J].国际放射医学核医学杂志,2012,36(2):94.[doi:10.3760/cma.j.issn.1673-4114.2012.02.009]
 WANG Qin,LIU Xiao-qiu,LI Jin,et al.Effects of interleukin-21 gene combined with different doses of γ-ray radiation on growth of breast carcinoma cells[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):94.[doi:10.3760/cma.j.issn.1673-4114.2012.02.009]
[3]石朔,李彪.促血管生成因子在治疗缺血性心脏病中的应用[J].国际放射医学核医学杂志,2013,37(6):355.[doi:10.3760/cma.j.issn.1673-4114.2013.06.008]
 SHI Shuo,LI Biao.Utility of the angiogenesis factors in the management of ischemic heart disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):355.[doi:10.3760/cma.j.issn.1673-4114.2013.06.008]
[4]郭睿,李彪.早期生长反应基因1启动子介导肿瘤基因-放疗的研究进展[J].国际放射医学核医学杂志,2010,34(4):206.[doi:10.3760/cma.j.issn.1673-4114.2010.04.004]
 GUO Rui,LI Biao.The progress of tumor gene-radiotherapy induced by Egr-1 promoter[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):206.[doi:10.3760/cma.j.issn.1673-4114.2010.04.004]
[5]陈凤华,李进,谭志军,等.Ad-Rb94联合γ射线照射对食管癌细胞生长的影响[J].国际放射医学核医学杂志,2010,34(2):119.[doi:10.3760/cma.j.issn.1673-4114.2010.02.017]
 CHEN Feng-hua,LI Jin,TAN Zhi-jun,et al.Effects of recombinant adenovirus mediated retinoblastoma gene 94 combined with γ-ray on growth of esophageal carcinoma cells[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):119.[doi:10.3760/cma.j.issn.1673-4114.2010.02.017]
[6]郭睿,李彪.钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2010,34(3):147.
 GUO Rui,LI Biao.Advances of radioiodine therapy of tumor induced by sodium iodide symporter gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):147.
[7]翟红彦,苏成海.基因治疗联合放射治疗恶性肿瘤的分子机制[J].国际放射医学核医学杂志,2009,33(2):113.[doi:10.3760/cma.j.issn.1673-4114.2009.02.015]
 ZHAI Hong-yan,SU Cheng-hai.Molecular mechanism of genetherapy combined radiotherapy for malignant tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):113.[doi:10.3760/cma.j.issn.1673-4114.2009.02.015]
[8]方圣伟,奚望,张宏.分子核医学的发展和应用前景[J].国际放射医学核医学杂志,2009,33(6):321.[doi:10.3760/cma.j.issn.1673-4114.2009.06.001]
 FANG Sheng-wei,XI Wang,ZHANG Hong.The developments and applications of molecular nuclear medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):321.[doi:10.3760/cma.j.issn.1673-4114.2009.06.001]
[9]张国鹏,张永学.心肌缺血性疾病基因治疗及分子影像监测进展[J].国际放射医学核医学杂志,2008,32(5):257.
 ZHANG Guo-peng,ZHANG Yong-xue.Advances in gene therapy of myocardial ischemia and the monitoring with molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):257.
[10]张俊,刘增礼.钠碘转运体基因介导的肿瘤放射性核素治疗研究[J].国际放射医学核医学杂志,2008,32(1):8.
 ZHA NG Jun,LIU Zeng-li.Sodium iodide symporter gene-mediated radionuclide therapy of tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):8.

备注/Memo

备注/Memo:
收稿日期:2013-12-02。
基金项目:国家自然科学基金(81301244,81171372);天津市应用基础及前沿技术研究计划项目(12JCZDJC26000)
通讯作者:谭建,Email:tanpost@163.com
更新日期/Last Update: 1900-01-01